GB-4362
Phase 1Small molecule
GB-4362 is one of 4 small molecule programs targeting Advanced Urothelial Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Advanced Urothelial Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Bavencio
EMD SeronoPhase 2
Padcev
PfizerPhase 1
GB-4362
GGenerate Biomedicines
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GB-4362. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- GGenerate Biomedicines